As a result, 12 genes were found to be downregulated following gilteritinib therapy, including CENPE, MCM4, GSPT1, MMS22L, DDX21, VDAC1, FDX1, OPA1, PDHX, ELOA, BCL3, and RACGP1, in EC, OC and GC TCGA cohort (Supplemental Fig. 4). Here, OPA1 is linked to gastric cancer.